Supplementary Table 1. Baseline characteristics of the TDF groups compared to the non-HBV infected control group and the propensity score-matched cohort

Characteristic	TDF (n=898)	Non-HBV-infected control (n=3,698)	*P*-value	TDF (n=368)	Non-HBV-infected control (n=1,472)	*P*-value
Age (years)	51.1±10.9	51.1±7.5	0.942	50.0±10.8	50.0±7.7	0.961
BMI	23.6±3.0	24.3±2.9	<0.001	23.8±2.9	23.9±2.8	0.559
Male sex (%)	587 (65.4)	2,818 (73.2)	0.001	264 (71.7)	1,081 (73.4)	0.460
Hypertension (%)	39 (4.4)	831 (21.6)	<0.001	19 (5.2)	81 (5.5)	0.611
DM (%)	79 (8.8)	252 (6.5)	0.083	20 (5.4)	78 (5.3)	0.906
Dyslipidemia (%)	29 (3.2)	1431 (37.2)	<0.001	14 (3.8)	60 (4.1)	0.486
TC at baseline (mg/dL)	173.8±35.1	184.2±34.4	<0.001	167.5±24.6	169.1±24.6	0.292

Values are presented as mean±standard deviation or number (%).

TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus; BMI, body mass index; DM, diabetes mellitus; TC, total cholesterol.